

**Prequalification Team Inspection services
WHO PUBLIC INSPECTION REPORT
(WHOPIR)**

Desk Assessment of Finished Pharmaceutical Product (FPP) Manufacturer

Part 1		General information
Company information		
Name of Manufacturer	Ajanta Pharma Limited	
Corporate address of manufacturer	Ajanta Pharma Limited Ajanta House, Charkop Kandivili (West), Mumbai 400067, India Tel: +91 22 66061270 66061209 Fax: 66061200 Cell: + 91 9545511337	
Inspected site		
Name & address of manufacturing site	Ajanta Pharma Limited, Z/103/A, Dahej SEZ-II, Bharuch, Gujarat, 392130, India	
Production Block/Unit	Not applicable	
Desk assessment details		
Date of review	10 June 2020	
Products covered by this desk assessment	MA092 - Artemether/Lumefantrine Tablet, Dispersible 20mg/120mg MA111 - Artemether/Lumefantrine Tablet 20mg/120mg	
Part 2		Summary of SRA/NRA inspection evidence considered (from most recent to last)
<i>USFDA, USA</i>	Dates of inspection:	17-22 June 2019
	Type of inspection:	Pre-approval inspection
	Block/Unit:	NA
	Type of products/Dosage forms covered:	Divalproex Sodium, Delayed Release Capsules, USP (Sprinkle), 125 mg per capsule
<i>USFD, USAA</i>	Dates of inspection:	23-27 July 2018
	Type of inspection:	Pre-approval inspection
	Block/Unit:	NA
	Type of products/Dosage forms covered:	Cholestyramine Powder for Oral Suspension
<i>USFDA, USA</i>	Dates of inspection:	5-9 Feb 2018
	Type of inspection:	Pre-approval inspection
	Block/Unit:	NA
	Type of products/Dosage forms covered:	Silodosin capsule 4mg & 8mg

<i>USFDA, USA</i>	Dates of inspection:		3-7 April 2017	
	Type of inspection:		Initial and pre-approval inspection	
	Block/Unit:		NA	
	Type of products/Dosage forms covered:		Ranolazine extended release tablets and Risperidone tablets	
Part 3	Summary of the last WHO inspection			
Date and conclusion of most recent WHO inspection	7-11 August 2017 Compliant			
Brief description of manufacturing activities	Manufacturing, packaging and testing of oral solid dosage forms (tablets, hard gelatin capsules, oral dry powder suspension) and oral jelly.			
General information about the company and manufacturing site	<p>Ajanta Pharma Limited (here after referred as “Ajanta”) was incorporated in 1973. Ajanta is involved in manufacturing and marketing of the pharmaceutical products in India and overseas. Ajanta’s global head quarter and corporate office is located at Kandivli, Mumbai. Ajanta employs over 7,000 personnel worldwide (including India) including sales, marketing, Research and Development (R&D), manufacturing, quality, regulatory, human resources, accounts, finance, secretarial, legal, administration and various other functions. In India, Ajanta has several branded generic products with therapeutic focus on cardiology, ophthalmology, dermatology, musculoskeletal and Over-the-counter (OTC) segments. Ajanta’s products are developed at the Research and Development (R&D) center located at Kandivli, Mumbai, India.</p> <p>Globally, Ajanta has eight manufacturing facilities, seven in India {six formulation facilities and one Active Pharmaceutical Ingredient (API) facility}, and one in Mauritius.</p> <p>Dahej site was constructed 2014 and started its operations in October 2015. Commercialization of the products being manufactured at the site started in April 2017.</p>			
Focus of the last WHO inspection	<i>PQP Number</i>	<i>Product</i>	<i>Strength</i>	<i>Dosage Form</i>
	MA092	Artemether /Lumefantrine	20mg/120mg	Dispersible Tablet
	MA111	Artemether /Lumefantrine	20mg/120mg	Tablet
Areas inspected	<ul style="list-style-type: none"> • Pharmaceutical quality system (PQS) • Good manufacturing practices for pharmaceutical products • Sanitation and hygiene • Qualification and validation • Complaints • Product recalls • Contract production, analysis and other activities 			

	<ul style="list-style-type: none"> • Self-inspection, quality audits and supplier audits and approval • Personnel • Training • Personal hygiene • Premises • Equipment • Materials • Documentation • Good practices in production • Good practices in quality control
Out of scope and restrictions (last WHO inspection)	Not applicable
WHO products covered by the last WHO inspection	Not applicable
Additional products covered by this desk assessment:	None
Abbreviations	Meaning
AHU	Air handling unit
API	Active pharmaceutical ingredient
BMR	Batch manufacturing record
BPR	Batch production record
CAPA	Corrective and preventive action
CC	Change control
GMP	Good manufacturing practices
NC	Non conformity
NRA	National regulatory agency
PQR	Product quality review
PQS	Pharmaceutical quality system
QA	Quality assurance
QC	Quality control
QCL	Quality control laboratory
QMS	Quality management system
QRM	Quality risk management
RA	Risk assessment
RCA	Root cause analysis
SOP	Standard operating procedure

Part 4	Summary of the assessment of supporting documentation
---------------	--

a) Manufacturing authorization and GMP certificate granted by the local authority:

The manufacturing licence was issued by the State Food and Drug Control Authority, Gujarat, India. The details are as follows:

- G/25/2080 (Form 25): Validity from 23/02/2020 to 22/02/2025
- G/28/1505 (Form 28): Validity from 23/02/2020 to 22/02/2025

The State Food and Drug Control Authority, Gujarat, India had issued a GMP certificate (18091020) based on an on-site GMP inspected conducted in August 2018. The GMP certificate is valid until with a validity until 23rd September 2021.

b) Site master file (SMF):

The site master file (DHJ/SMF/001 Version No 05 effective date 8th May 2020) was provided by the applicant. The SMF was supported with required Annexes. In general, the SMF provided a high-level overview of the manufacturing activities being carried out at the Dahej site of Ajanta Pharma.

c) List of regulatory inspections performed in the last 3 years and their outcome:

The following is the list of all regulatory inspections carried out at Ajanta Pharma' Dahej manufacturing facility:

Sr. No.	Inspection Date	Regulatory Authority/Agency	Report/ Certificate Date
1	6 th Jan, 2015	Food & Drug Administration, Gujarat	23 rd Feb, 2015
2	20 th Jul, 2016	Food & Drug Administration, Gujarat	28 th Jul, 2016
3	8 th to 9 th Sep, 2016 and 30 th Sep, 2016	Central Drug Standards Control Organization (CDSCO), India	1 st Oct, 2016
4	3 rd to 7 th Apr, 2017	United State Food & Drug Administration	18 th Aug, 2017
5	24 th to 26 th Apr, 2017	Drug Administration and Drug Authority of Ethiopia	26 th Sep, 2017
6	7 th to 11 th Aug, 2017	WHO, Geneva	11 th Sep, 2017
7	24 th to 25 th Oct, 2017	Ministry of Health & Population, Yemen	18 th Dec, 2018

Sr. No.	Inspection Date	Regulatory Authority/Agency	Report/ Certificate Date
8	11 th to 12 th Sep, 2017	Central Drug Standards Control Organization (CDSCO), India	25 th Oct, 2017
9	14 th to 15 th Dec, 2017	Medicines Control authority of Zimbabwe	4 th July, 2018
10	5 th to 9 th Feb, 2018	United State Food & Drug Administration	09 th Apr, 2018
11	19 th to 20 th Apr, 2018	United Laboratories, Inc. Philippines	13 th May, 2018
12	23 rd to 27 th Jul, 2018	United State Food & Drug Administration	13 th Sep, 2018
13	07 th to 8 th Aug, 2018	Central Drug Standards Control Organization (CDSCO), India	12 th Sep, 2018
14	22 nd to 23 th Oct, 2018	Ministry of Health Pharmacy and Poisons Board, Kenya	23 rd Oct, 2018
15	24 th to 25 th Jan, 2019	National Drug Authority, Uganda	20 th Dec, 2019
16	17 th to 22 nd Jun, 2019	United State Food & Drug Administration	15 th Aug 2019

d) List of all the products and dosage forms manufactured on-site:

The applicant has provided a list of all products manufactured at Dahej site. The list included proprietary names and international non-proprietary names (INN) manufactured on-site. The site produces medicinal products of different therapeutic areas e.g. antibiotics, antimalarials, anticonvulsant, antidepressant, antidiabetic, antiepileptic, antihypertensive, antipsychotic etc.

e) Most recent product quality review(s) (PQR)(s) of the concerned WHO product(s):

The PQR for Artemether 20mg and Lumefantrine 120mg tablets for the review period April 2019 to March 2020 was provided. A total of 30 batches were produced during this period. In general, the PQR provided a review of starting materials, intermediates, finished products and was supported with graphical presentation and analysis.

The PQR for Artemether 20mg and Lumefantrine 120mg dispersible tablets for the review period April 2019 to March 2020 was provided. A total of 13 batches were produced during this period. In general, the PQR provided a review of starting materials, intermediates, finished products and was supported with graphical presentation and analysis.

f) Batch manufacturing and packaging record(s), including the analytical part, for the most recently released batch of relevant product(s):

The batch manufacturing (DJ0310B), batch packaging (DJ0310B) and analytical record (DJ0310B) of Artemether 20mg and Lumefantrine 120mg tablets and batch manufacturing (DJ0530B), batch packaging (DJ0530B) and analytical record (DJ0530B) of Artemether 20mg and Lumefantrine 120mg Dispersible tablets was provided by the applicant.

g) Master batch manufacturing and packaging record(s) of the product(s) of interest:

The copies of the blank batch manufacturing and packaging record of Artemether 20mg and Lumefantrine 120mg tablets and Artemether 20mg (Product code: 4000485 and 5001352) and Lumefantrine 120mg dispersible tablets (Product code: 4000585 and 5001329) was provided.

h) Recalls in the past three years related to products with quality defects:

The manufacturer confirmed that there was no recall initiated in the past three years related to any products manufactured at Ajanta Pharma Limited, Dahej.

i) Confirmation by the senior quality assurance representative that a full self-inspection or external audit dedicated to the product(s) has been performed and all matters dealt with:

The manufacturer confirmed that self-inspection is being performed at regular interval covering GMP requirements.

j) copy of any warning letter, or equivalent regulatory action, issued by any authority to which the site provides or has applied to provide the product:

The manufacturer confirmed that there was no warning letter or no critical observation issued by any regulatory authority.

k) Out-of-stock situations:

The manufacturer has confirmed that there is no out of stock situation taken place during last three years and they do not foresee any in future.

l) Additional documents submitted:

The inspection conducted by the USFDA in 2017, 2018 and 2019 did not cover WHO Prequalified products as part of the scope of their inspection. The same dosage form was part of the scope of their inspections.

Part 5	Conclusion – Desk assessment outcome
---------------	---

Based on the previous WHO inspections and on the GMP evidence received and reviewed, it is considered that a desk assessment is acceptable in lieu of a WHO onsite inspection. The site **Ajanta Pharma Limited** located at **Plot No Z/103/A, Dahej SEZ Part II, District: Bharuch, Gujarat, India** is operating at an acceptable level of compliance with WHO GMP guidelines.

This WHOPIR will remain valid until 1st August 2022, provided that the outcome of any inspection conducted during this period is positive.

Part 6	List of guidelines referenced in this inspection report
---------------	--

1. WHO good manufacturing practices for pharmaceutical products: main principles. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-eighth Report. Geneva, World Health Organization, 2014 (WHO Technical Report Series, No. 986), Annex 2. **Short name: WHO GMP Guidelines** or **TRS No. 986, Annex 2**
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/trs_986/en/
2. WHO good manufacturing practices for active pharmaceutical ingredients. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth Report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 2. **Short name: WHO GMP for APIs** or **WHO TRS No. 957, Annex 2**
<http://apps.who.int/medicinedocs/documents/s20119en/s20119en.pdf>
3. WHO guidance on good practices for desk assessment of compliance with good manufacturing practices, good laboratory practices and good clinical practices for medical products regulatory decisions. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-second Report. Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1010), Annex 9. **Short name: WHO TRS 1010, Annex 9**
https://www.who.int/medicines/areas/quality_safety/quality_assurance/TRS1010annex9.pdf?ua=1
4. WHO Good Manufacturing Practices: water for pharmaceutical use. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fourth-sixth Report. Geneva, World Health Organization, 2012 (WHO Technical Report Series, No. 970), Annex 2.
Short name: WHO TRS No. 970, Annex 2
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/trs_970/en/
5. WHO guidelines for sampling of pharmaceutical products and related materials. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth Report. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 929), Annex 4.
Short name: WHO TRS No. 929, Annex 4
http://whqlibdoc.who.int/trs/WHO_TRS_929_eng.pdf?ua=1

6. Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-second Report Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1010), Annex 8. **Short name: WHO HVAC Guidelines or WHO TRS No. 1010, Annex 8**
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/trs_1010/en/
7. Supplementary guidelines on good manufacturing practices: validation. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth Report. Geneva, World Health Organization, 2006 (WHO Technical Report Series, No. 937), Annex 4.
Short name: WHO TRS No. 937, Annex 4
http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf?ua=1
8. WHO Good Practices for Pharmaceutical Quality Control Laboratories. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth Report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957, Annex 1).
Short name: WHO GPPQCL guidelines or WHO TRS No. 957), Annex 1
<http://www.who.int/medicines/publications/44threport/en/>
9. WHO Good Practices for Pharmaceutical Products Containing Hazardous Substances. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth Report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 2.
Short name: WHO TRS No. 957, Annex 2
<http://www.who.int/medicines/publications/44threport/en/>
10. WHO good manufacturing practices for sterile pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 6.
Short name: WHO TRS No. 961, Annex 6
http://whqlibdoc.who.int/trs/WHO_TRS_961_eng.pdf?ua=1
11. WHO guidelines on transfer of technology in pharmaceutical manufacturing WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 7.
Short name: WHO TRS No. 961, Annex 7
http://whqlibdoc.who.int/trs/WHO_TRS_961_eng.pdf?ua=1
12. Model guidance for the storage and transport of time-and temperature-sensitive pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 9.
Short name: WHO TRS No. 961, Annex 9
http://whqlibdoc.who.int/trs/WHO_TRS_961_eng.pdf?ua=1

13. General guidelines for the establishment maintenance and distribution of chemical reference substances. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first Report Geneva, World Health Organization 2007 (WHO Technical Report Series, No.943) Annex 3.
Short name: WHO TRS No. 943, Annex 3
http://whqlibdoc.who.int/trs/WHO_TRS_943_eng.pdf?ua=1
14. WHO good practices for pharmaceutical microbiology laboratories. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 2.
Short name: WHO TRS No. 961, Annex 2
http://whqlibdoc.who.int/trs/WHO_TRS_961_eng.pdf?ua=1
15. WHO guidelines on quality risk management. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-seventh Report Geneva, World Health Organization, 2013 (WHO Technical Report Series, No. 981), Annex 2.
Short name: WHO TRS No. 981, Annex 2
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/trs_981/en/
16. WHO guidelines on variation to a prequalified product. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-seventh Report Geneva, World Health Organization, 2013 (WHO Technical Report Series, No. 981), Annex 3. **Short name: WHO TRS No. 981, Annex 3**
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/trs_981/en/
17. WHO guidelines for drafting a site master file. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 14. **Short name: WHO TRS No. 961, Annex 14**
http://whqlibdoc.who.int/trs/WHO_TRS_961_eng.pdf?ua=1
18. WHO Guidelines on good manufacturing practices: validation, Appendix 7: non-sterile process validation. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth Report Geneva, World Health Organization, 2015 (WHO Technical Report Series, No. 992), Annex 3.
Short name: WHO TRS No. 992, Annex 3
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/WHO_TRS_992_web.pdf
19. WHO General guidance on hold-time studies WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth Report Geneva, World Health Organization, 2015 (WHO Technical Report Series, No. 992), Annex 4.
Short name: WHO TRS No. 992, Annex 4
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/WHO_TRS_992_web.pdf

20. WHO Technical supplements to Model Guidance for storage and transport of time – and temperature – sensitive pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth Report Geneva, World Health Organization, 2015 (WHO Technical Report Series, No. 992), Annex 5. **Short name: WHO TRS No. 992, Annex 5**
http://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/WHO_TRS_992_web.pdf
21. Guidance on good data and record management practices. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fiftieth Report Geneva, World Health Organization, 2016 (WHO Technical Report Series, No. 996), Annex 5.
Short name: WHO GDRMP guidelines or WHO TRS No. 996, Annex 5
http://www.who.int/medicines/publications/pharmprep/WHO_TRS_996_annex05.pdf
22. WHO general guidance on variations to multisource pharmaceutical products. *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fiftieth Report* Geneva, World Health Organization, 2016 (WHO Technical Report Series, No. 996), Annex 10.
Short name: WHO TRS No. 996, Annex 10
http://www.who.int/medicines/publications/pharmprep/WHO_TRS_996_annex10.pdf
23. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-second Report Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1010), Annex 10.
Short name: WHO TRS No. 1010, Annex 10
http://www.who.int/medicines/publications/pharmprep/WHO_TRS_996_annex10.pdf